Antiseptic Cleansing to Reduce Vertical Transmission of Pathogens to Neonates: The NeoVT-AMR Randomized
By
Emily Beales
Michelle N. Clements
Nicholas A. Feasey
David Lissauer
Maranatha Banda
Bertha Maseko
Julia A. Bielicki
Samantha Lissauer
Aisleen Bennett
Kondwani Kawaza
Luis A. Gadama
A. Sarah Walker
Mike Sharland
Louise F. Hill
June 11, 2026
Clinical Scorecard: Cleansing with Antiseptics to Mitigate Pathogen Transmission to Newborns: Findings from the NeoVT-AMR Trial
At a Glance
Category Detail
Condition Neonatal sepsis due to vertical transmission of pathogens Key Mechanisms Use of antiseptics to reduce bacterial load in maternal genital tract and neonatal skin Target Population Laboring women and newborns in low-income countries Care Setting Antenatal and labor wards, neonatal and postnatal wards
Key Highlights
Infection is a major cause of neonatal mortality, particularly in low-income countries. Chlorhexidine (CHG) and octenidine with phenoxyethanol (OHP) are potential antiseptic strategies. Evidence for clinical benefit of antiseptics in reducing early-onset sepsis is mixed. The trial evaluated multiple antiseptic regimens and application strategies. Large pragmatic trials are needed to determine effective antiseptic use. Guideline-Based Recommendations
Diagnosis
Identify early-onset sepsis in neonates within 72 hours of birth. Management
Consider antiseptic application to reduce bacterial load during labor. Monitoring & Follow-up
Assess skin condition scores and total bacterial load in both maternal and neonatal populations. Risks
Monitor for adverse effects related to antiseptic application. Patient & Prescribing Data
Laboring women and newborns in healthcare facilities
Antiseptics applied vaginally or topically to reduce infection risk.
Clinical Best Practices
Use antiseptics in accordance with WHO recommendations. Ensure informed consent is obtained from participants. Conduct regular monitoring of bacterial load and skin condition. Related Resources & Content
